• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Bernie Sanders: 'Getting Sick In America Should Not Mean Going Bankrupt, Losing Your Home, Car, Or Life Savings'

    7/15/24 9:36:15 PM ET
    $BIIB
    $BMY
    $JNJ
    $MRK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BIIB alert in real time by email

    Sen. Bernie Sanders (I-Vt.) recently expressed his concerns about the high cost of medical care in the United States, highlighting the financial burden it places on patients.

    What Happened: On Monday, Sanders took to X to voice his concerns about the high cost of healthcare in the United States. He pointed out that the U.S. is the only major country where an emergency hospital visit can lead to financial ruin for patients. He stated, “Getting sick in America should not mean going bankrupt, losing your home, car, or life savings.”

    Sanders shared a video featuring various medical professionals who shared stories about the high cost of medical care in the U.S.

    We are the only major country on Earth where an emergency visit to a hospital can cause patients to lose their homes and their life savings because of the high cost of medical care.

    Getting sick in America should not mean going bankrupt, losing your home, car, or life savings. pic.twitter.com/5oxoa8QsVK

    — Bernie Sanders (@SenSanders) July 15, 2024

    See Also: Charlie Munger Said Trump Was ‘Right’ On Need For Having ‘Way More Control Over Our Borders’: ‘They Hate Him So Much That They’re Against Him Even When He’s Right’

    Why It Matters: Sanders has been vocal about the high cost of healthcare in the U.S. In March, he criticized the “outrageous” prices of diabetes drug Ozempic by Novo Nordisk (NYSE:NVO) and considered holding hearings on the issue. In June, he called the price tag of Alzheimer’s treatment Leqembi, produced by Eisai Co Ltd (OTC:ESALF) and Biogen Inc (NASDAQ:BIIB), ‘unconscionable’.

    In February, he blasted the high prices of lifesaving drugs by Johnson & Johnson (NYSE:JNJ), Merck (NYSE:MRK) and Bristol-Myers Squibb (NYSE:BMY) during a Senate hearing on Medicare. He also highlighted the case of a woman in Nebraska who died of cancer after setting up a GoFundMe campaign to pay for her medication.

    According to a Federal Reserve report, 28% of Americans had to forego some form of medical care in 2022 due to high costs, marking a 4 percentage-point increase from the previous year.

    Photo by Sheila Fitzgerald on Shutterstock

    Read Next:

    • Marjorie Taylor Greene Slams Kamala Harris, Accusing Vice President Of Hiding ‘A Secret And Lie To America’: ‘She Is Perhaps The Biggest Of All Liars’

    This story was generated using Benzinga Neuro and edited by Shivdeep Dhaliwal

    Get the next $BIIB alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BIIB
    $BMY
    $JNJ
    $MRK

    CompanyDatePrice TargetRatingAnalyst
    Novo Nordisk A/S
    $NVO
    3/18/2026Underperform
    Bernstein
    Novo Nordisk A/S
    $NVO
    3/18/2026$175.00Outperform
    Bernstein
    Novo Nordisk A/S
    $NVO
    3/10/2026$42.00Buy → Hold
    TD Cowen
    Novo Nordisk A/S
    $NVO
    3/3/2026$40.00Underweight → Equal-Weight
    Morgan Stanley
    Novo Nordisk A/S
    $NVO
    3/2/2026$41.00Buy → Neutral
    Goldman
    Merck & Company Inc.
    $MRK
    2/25/2026$142.00Outperform
    RBC Capital Mkts
    Bristol-Myers Squibb Company
    $BMY
    2/25/2026$60.00Sector Perform
    RBC Capital Mkts
    Novo Nordisk A/S
    $NVO
    2/24/2026Buy → Hold
    Kepler
    More analyst ratings

    $BIIB
    $BMY
    $JNJ
    $MRK
    SEC Filings

    View All

    Amendment: SEC Form 13F-HR/A filed by Johnson & Johnson

    13F-HR/A - JOHNSON & JOHNSON (0000200406) (Filer)

    3/18/26 11:57:35 AM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form 13F-HR/A filed by Johnson & Johnson

    13F-HR/A - JOHNSON & JOHNSON (0000200406) (Filer)

    3/18/26 11:38:20 AM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Novo Nordisk A/S

    6-K - NOVO NORDISK A S (0000353278) (Filer)

    3/17/26 7:10:41 AM ET
    $NVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BIIB
    $BMY
    $JNJ
    $MRK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Hewson Marillyn A

    4 - JOHNSON & JOHNSON (0000200406) (Issuer)

    3/12/26 9:31:29 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Pinto Daniel E

    4 - JOHNSON & JOHNSON (0000200406) (Issuer)

    3/12/26 8:39:41 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Woods Eugene A.

    4 - JOHNSON & JOHNSON (0000200406) (Issuer)

    3/12/26 8:37:30 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BIIB
    $BMY
    $JNJ
    $MRK
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Bernstein initiated coverage on Novo Nordisk A/S

    Bernstein initiated coverage of Novo Nordisk A/S with a rating of Underperform

    3/18/26 3:58:44 PM ET
    $NVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Bernstein initiated coverage on Novo Nordisk A/S with a new price target

    Bernstein initiated coverage of Novo Nordisk A/S with a rating of Outperform and set a new price target of $175.00

    3/18/26 1:57:24 PM ET
    $NVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Novo Nordisk A/S downgraded by TD Cowen with a new price target

    TD Cowen downgraded Novo Nordisk A/S from Buy to Hold and set a new price target of $42.00

    3/10/26 8:39:23 AM ET
    $NVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BIIB
    $BMY
    $JNJ
    $MRK
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    September 26, 2024 - FDA Approves Drug with New Mechanism of Action for Treatment of Schizophrenia

    For Immediate Release: September 26, 2024 Today, the U.S. Food and Drug Administration approved Cobenfy (xanomeline and trospium chloride) capsules for oral use for the treatment of schizophrenia in adults. It is the first antipsychotic drug approved to treat schizophrenia that targets cholinergic receptors as opposed to dopamine receptors, which has long been the standard of care.   “Schizophrenia is a leading

    9/26/24 6:42:20 PM ET
    $BMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for VUMERITY issued to BIOGEN INC

    Submission status for BIOGEN INC's drug VUMERITY (ORIG-1) with active ingredient DIROXIMEL FUMARATE has changed to 'Approval' on 09/12/2024. Application Category: NDA, Application Number: 761347, Application Classification: Type 3 - New Dosage Form

    9/16/24 6:52:10 AM ET
    $BIIB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    FDA Approval for VUMERITY issued to BIOGEN INC

    Submission status for BIOGEN INC's drug VUMERITY (SUPPL-17) with active ingredient DIROXIMEL FUMARATE has changed to 'Approval' on 09/11/2024. Application Category: NDA, Application Number: 211855, Application Classification: Manufacturing (CMC)

    9/16/24 6:24:32 AM ET
    $BIIB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BIIB
    $BMY
    $JNJ
    $MRK
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    $BIIB
    $BMY
    $JNJ
    $MRK
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    FDA approves Novo Nordisk's new Wegovy® HD injection, delivering the highest weight loss to date for a Wegovy® injection, adding to its already expansive clinical profile

    Average weight loss of ~21% at 72 weeks in adults with obesity if all patients stayed on treatment* with Wegovy® HD (~19% regardless of whether patients stayed on treatment**) in the STEP UP trial1In the STEP UP trial, about one in three trial participants taking Wegovy® HD achieved 25% weight loss or higher1This approval for Wegovy® further expands its already robust label inclusive of multiple formulations, including Wegovy® pill, and indications not available with other GLP-1 weight loss medicinesPLAINSBORO, N.J., March 19, 2026 /PRNewswire/ -- Novo Nordisk today announced US Food and Drug Administration (FDA) approval of a new higher dose of Wegovy®, Wegovy® HD (semaglutide) injection 7.

    3/19/26 12:04:00 PM ET
    $NVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Biogen to Present New Late-Breaking Litifilimab Phase 2 AMETHYST Data in Cutaneous Lupus Erythematosus at 2026 American Academy of Dermatology Annual Meeting

    Late-breaking AMETHYST Part A study results to be presented, showing safety and efficacy of litifilimab in cutaneous lupus erythematosus (CLE)Litifilimab was recently granted Breakthrough Therapy Designation by the FDA for CLE; AMETHYST Part A results supported the designationCLE is a serious autoimmune disease that impacts the daily lives of patients and can lead to permanent scarring and disfigurement when left untreated, and has no targeted treatment option CAMBRIDGE, Mass., March 19, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (NASDAQ:BIIB) today announced upcoming scientific presentations at the 2026 American Academy of Dermatology (AAD) Annual Meeting, taking place March 27-31. Late-breaki

    3/19/26 7:30:00 AM ET
    $BIIB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Bristol Myers Squibb to Report Results for First Quarter 2026 on April 30, 2026

    Bristol Myers Squibb (NYSE:BMY) will announce results for the first quarter of 2026 on Thursday, April 30, 2026. Company executives will review financial results with the investment community during a conference call beginning at 8:00 a.m. ET. Investors and the general public are invited to listen to a live audio webcast of the call at http://investor.bms.com. Materials related to the call will be available on the company's Investor Relations website prior to the start of the conference call. A replay of the webcast will be available here approximately three hours after the conference call concludes. About Bristol Myers Squibb: Transforming Patients' Lives Through Science At Bristol

    3/19/26 6:59:00 AM ET
    $BMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Head of Pharm Ops and Tech Murphy Nicole bought $585 worth of shares (3 units at $195.03), increasing direct ownership by 0.02% to 19,611 units (SEC Form 4)

    4 - BIOGEN INC. (0000875045) (Issuer)

    2/17/26 8:16:40 PM ET
    $BIIB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Dorsa Caroline bought $151,559 worth of shares (1,235 units at $122.72), increasing direct ownership by 5% to 27,842 units (SEC Form 4)

    4 - BIOGEN INC. (0000875045) (Issuer)

    5/5/25 4:17:10 PM ET
    $BIIB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    EVP,Chief Med.Offr.,Drug Dev. Hirawat Samit bought $202,215 worth of shares (4,250 units at $47.58), increasing direct ownership by 5% to 83,513 units (SEC Form 4)

    4 - BRISTOL MYERS SQUIBB CO (0000014272) (Issuer)

    4/29/25 6:14:13 PM ET
    $BMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BIIB
    $BMY
    $JNJ
    $MRK
    Financials

    Live finance-specific insights

    View All

    Bristol Myers Squibb to Report Results for First Quarter 2026 on April 30, 2026

    Bristol Myers Squibb (NYSE:BMY) will announce results for the first quarter of 2026 on Thursday, April 30, 2026. Company executives will review financial results with the investment community during a conference call beginning at 8:00 a.m. ET. Investors and the general public are invited to listen to a live audio webcast of the call at http://investor.bms.com. Materials related to the call will be available on the company's Investor Relations website prior to the start of the conference call. A replay of the webcast will be available here approximately three hours after the conference call concludes. About Bristol Myers Squibb: Transforming Patients' Lives Through Science At Bristol

    3/19/26 6:59:00 AM ET
    $BMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NeOnc Technologies Reports Phase 1 Dose-Escalation Results for Dosing and Toxicity and Determination of Recommended Phase 2 Dose for Oral NEO212; Management to Host KOL Conference Call Today at 9 a.m. ET

    CALABASAS, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ:NTHI) ("NeOnc" or the "Company"), a multi-Phase 2 clinical-stage biopharmaceutical company developing novel therapies for central nervous system (CNS) cancers, today announced data from the dose-escalation portion of its Phase 1/2 clinical trial for NEO212, the Company's novel oral bio-conjugated therapy and will host a conference call to discuss the data today at 9:00am ET. NeOnc has formally notified the FDA that the Phase 1 dose-escalation portion of the NEO212-01 Phase 1/2 clinical trial has reached Maximum Tolerated Dose (MTD) at Cohort 5 (810 mg, Days 1–5, 28-day cycle) following a second

    3/4/26 8:00:00 AM ET
    $MRK
    $NTHI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Johnson & Johnson to Host Investor Conference Call on First-Quarter Results

    Johnson & Johnson (NYSE:JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Tuesday, April 14th to review first-quarter results. Joaquin Duato, Chairman and Chief Executive Officer, Joseph J. Wolk, Executive Vice President and Chief Financial Officer and Darren Snellgrove, Vice President, Investor Relations will host the call. The question and answer portion of the call will also include additional members of Johnson & Johnson's executive team. Investors and other interested parties can access the webcast/conference call in the following ways: The webcast and presentation material are accessible at Johnson & Johnson's website www.investor.jnj.com. A replay of

    3/2/26 4:30:00 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BIIB
    $BMY
    $JNJ
    $MRK
    Leadership Updates

    Live Leadership Updates

    View All

    Merck Evolves Human Health Operating Structure to Support Portfolio Execution

    Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today highlighted steps to evolve the structure of its Human Health organization to ensure strong commercial execution of launches across diverse therapeutic areas, positioning the company for continued commercial success. As part of this evolution, Merck is organizing its Human Health business into an Oncology Business Unit and a Specialty, Pharma & Infectious Diseases Business Unit. This structure will enable Merck to sustain long-term leadership in oncology, while maintaining a sharp focus in support of a growing number of launches across an increasingly broad and diverse portfolio. In support of the new Human He

    2/23/26 6:45:00 AM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Merck to Acquire Cidara Therapeutics, Inc., Diversifying Its Portfolio to Include Late-Phase Antiviral Agent

    CD388 is an investigational long-acting, strain-agnostic antiviral agent currently in Phase 3, designed to prevent influenza infection in individuals at higher risk of influenza complications Acquisition aligns with Merck's science-led business development strategy, diversifying and expanding the company's pipeline Merck (NYSE:MRK), known as MSD outside of the United States and Canada, and Cidara Therapeutics, Inc. (NASDAQ:CDTX) ("Cidara"), a biotechnology company developing drug-Fc conjugate (DFC) therapeutics, today announced that the companies have entered into a definitive agreement under which Merck, through a subsidiary, will acquire Cidara for $221.50 per share in cash, for a tot

    11/14/25 6:45:00 AM ET
    $CDTX
    $MRK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    /C O R R E C T I O N -- National Association of Corporate Directors/

    In the news release, Global Leaders Jesús Mantas and Wes Bricker Join NACD Board of Directors, issued 10-Oct-2025 by National Association of Corporate Directors over PR Newswire, we are advised by the company that the third paragraph, the end of the last line, should read "IBM Business Transformation Services" instead of "IBM Consulting Business Transformation Services" as originally issued inadvertently. The complete, corrected release follows: Global Leaders Jesús Mantas and Wes Bricker Join NACD Board of Directors Seasoned executives bring deep expertise in innovation, governance, and business to strengthen NACD's leadership board excellence WASHINGTON, Oct. 10, 2025 /PRNewswire/ -- Th

    10/10/25 10:00:00 AM ET
    $BIIB
    $IFF
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Major Chemicals
    Industrials

    $BIIB
    $BMY
    $JNJ
    $MRK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Biogen Inc.

    SC 13G/A - BIOGEN INC. (0000875045) (Subject)

    11/12/24 1:24:28 PM ET
    $BIIB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Biogen Inc.

    SC 13G/A - BIOGEN INC. (0000875045) (Subject)

    11/4/24 11:20:12 AM ET
    $BIIB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by Biogen Inc.

    SC 13G - BIOGEN INC. (0000875045) (Subject)

    10/16/24 12:11:53 PM ET
    $BIIB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care